Kolexia
Colomba-Blameble Emeline Oncologie médicale
Colomba-Blameble Emeline
Oncologie médicale
Chu De Martinique Site De Clarac
Fort-de-France, France
170 Activités
84 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Néphrocarcinome COVID-19 Tumeurs de la prostate Tumeurs de l'endomètre Tumeurs du rein Tumeurs de l'ovaire Tumeurs prostatiques résistantes à la castration Carcinome épithélial de l'ovaire

Collaborateurs

Voir plus
Albiges Laurence
Albiges Laurence
Gustave-Roussy, Villejuif, France
Escudier Bernard
Escudier Bernard
Gustave-Roussy, Villejuif, France
Flippot Ronan
Flippot Ronan
Gustave-Roussy, Villejuif, France
Derosa Lisa
Derosa Lisa
Gustave-Roussy, Villejuif, France

Industries

Voir plus
Ipsen
30 collaboration(s)
Dernière en 2022
B3TSI
15 collaboration(s)
Dernière en 2023
A+A
14 collaboration(s)
Dernière en 2023
MSD
14 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Correction: Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers.
Cell death & disease   14 février 2024
Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors.
Clinical cancer research : an official journal of the American Association for Cancer Research   02 novembre 2023
Development of Novel Models of Aggressive Variants of Castration-resistant Prostate Cancer.
European urology oncology   26 octobre 2023
Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]): A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer
Essai Clinique (Eisai)   17 octobre 2023
Clinical utility of plasma ctDNA sequencing in metastatic urothelial cancer.
European journal of cancer (Oxford, England : 1990)   06 octobre 2023
748P Outcomes for patients (pts) with advanced endometrial cancer (aEC) who completed pembrolizumab (pembro) and continued lenvatinib (LEN) in the phase III Study 309/KEYNOTE-775
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers.
Journal for immunotherapy of cancer   14 septembre 2023
Efficacy and safety of cabozantinib rechallenge in metastatic renal cell carcinoma: A retrospective multicentric study.
European journal of cancer (Oxford, England : 1990)   18 août 2023
MATCH-R: A Prospective Trial to Study the Evolution of Clonal Architecture of Tumors From Patients Treated With Molecular Targeted Agents
Essai Clinique (Gustave-Roussy)   17 août 2023
A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA.
European urology   02 juin 2023